VivaVision Biotech files for HKEX listing with CICC as sole sponsor; both core ophthalmic products in Phase III trials

NewTimeSpace News: On 28 August 2026, VivaVision Biotech (Zhejiang) Co., Ltd. filed a listing application with HKEX, with CICC acting as the sole sponsor. Founded in 2016, the Company is a clinical-stage biotech company focused on the ophthalmic field. Leveraging its technology platforms in small-molecule drug discovery for ophthalmic diseases, advanced formulation development and translational medicine research, the Company is building a product pipeline covering various ophthalmic indications of the ocular surface and fundus.

The Company has two core products. VVN461 (high dose) is a high-dose formulation of the VVN461 eye drop, a novel selective dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), with non-infectious anterior uveitis (NIAU) as its primary indication; the Company has initiated a Phase III clinical trial of VVN461 (high dose) in NIAU patients in China. VVN001 is a second-generation lymphocyte function-associated antigen-1 (LFA-1) antagonist, an eye drop for the treatment of moderate-to-severe dry eye disease (DED); the Company has also initiated a Phase III clinical trial of VVN001 in China. As of the last practicable date, apart from the core products, the Company has three other clinical-stage drug candidates.

During the track record period, the Company engaged contract development and manufacturing organizations (CDMOs) to manufacture its drug candidates for preclinical and clinical use, and intends to continue cooperating with contract manufacturing organizations after regulatory approval to achieve future commercial production of its core products; the Company may also consider building in-house manufacturing capabilities in the future.

The Company is actively developing commercialization plans and expects to launch multiple potential products in the coming years, taking into account key factors including pricing, dosing regimens, patient economics, social and demographic characteristics, market access and reimbursement policies. As of the last practicable date, the Company has no approved drugs and has therefore not formulated any specific pricing strategy for its drug candidates; its primary commercialization approach will focus on collaboration with well-known pharmaceutical companies, supported by a dedicated in-house team with strong medical and scientific backgrounds.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.